These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1344 related articles for article (PubMed ID: 28682222)
1. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222 [TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747 [TBL] [Abstract][Full Text] [Related]
3. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000 [TBL] [Abstract][Full Text] [Related]
4. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403 [TBL] [Abstract][Full Text] [Related]
5. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Tappenden P; Jones R; Paisley S; Carroll C Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499 [TBL] [Abstract][Full Text] [Related]
6. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Shi Y; Wan X; Tan C; Li J; Peng L Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066 [TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994 [TBL] [Abstract][Full Text] [Related]
9. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C Value Health; 2013; 16(2):288-96. PubMed ID: 23538180 [TBL] [Abstract][Full Text] [Related]
12. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083 [TBL] [Abstract][Full Text] [Related]
13. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451 [TBL] [Abstract][Full Text] [Related]
16. Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States. Gathirua-Mwangi WG; Sethi H; Afable MG; Bhattacharyya D; Khan T J Med Econ; 2021; 24(1):1164-1172. PubMed ID: 34529522 [TBL] [Abstract][Full Text] [Related]
17. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587 [TBL] [Abstract][Full Text] [Related]
18. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184 [TBL] [Abstract][Full Text] [Related]
20. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]